Mythic Therapeutics, Inc.

Mythic Therapeutics, Inc. company information, Employees & Contact Information

Explore related pages

Mythic Therapeutics, Inc. email format Mythic Therapeutics, Inc. management contacts

Related company profiles:

Mythic Therapeutics is a product-platform company that is pioneering a powerful new approach to improving the effectiveness of antibody-drug conjugates (ADCs) and other antibody-based therapeutics. Our technology dramatically increases therapeutic potency without compromising safety, thereby unlocking the full potential of targeted therapies against a broad array of tumor targets. At Mythic, we focus on patient-centered science and are driven to leave a lasting impact on cancer care.

Company Details

Employees
62
Address
100 Beaver St, Waltham,massachusetts 02453,united States
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
Website
http://www.mythictx.com
Keywords
Biotechnology, Biologics, Oncology, Pharmaceuticals, Research & Development.
HQ
Waltham, Massachusetts
Competitors
enGene, Vertex Pharmaceuticals, Beam Therapeutics, Kymera Therapeutics, Viridian Therapeutics, Inc., Mersana Therapeutics, Dragonfly Therapeutics, Inc., Ventus Therapeutics, Tessera Therapeutics, Tango Therapeutics.
Looking for a particular Mythic Therapeutics, Inc. employee's phone or email?

Mythic Therapeutics, Inc. Questions

News

Mythic Therapeutics Presents Preclinical Data Demonstrating Potent Efficacy of MYTX-011 Across a Broad Range of Tumor Xenograft Models Harboring Clinically Relevant Mutations at the American Association for Cancer Research (AACR) Annual Meeting - Yahoo Finance

Mythic Therapeutics Presents Preclinical Data Demonstrating Potent Efficacy of MYTX-011 Across a Broad Range of Tumor Xenograft Models Harboring Clinically Relevant Mutations at the American Association for Cancer Research (AACR) Annual Meeting Yahoo Finance

Mythic Therapeutics Presents Compelling Efficacy Data from its Phase 1 KisMET-01 Study Supporting Best-in-Class Potential of Novel cMET- ADC, MYTX-011, in Non-Small Cell Lung Cancer at the American Society of Clinical Oncology (ASCO) Annual Meeti - Business Wire

Mythic Therapeutics Presents Compelling Efficacy Data from its Phase 1 KisMET-01 Study Supporting Best-in-Class Potential of Novel cMET- ADC, MYTX-011, in Non-Small Cell Lung Cancer at the American Society of Clinical Oncology (ASCO) Annual Meeti Business Wire

Mythic Therapeutics Appoints George Eliades, Ph.D., as CEO - citybiz

Mythic Therapeutics Appoints George Eliades, Ph.D., as CEO citybiz

Mythic Therapeutics to Present Updated Dose Escalation Data from Phase 1 KisMET-01 Study on MYTX-011 at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting - Business Wire

Mythic Therapeutics to Present Updated Dose Escalation Data from Phase 1 KisMET-01 Study on MYTX-011 at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting Business Wire

Mythic Therapeutics to Present Compelling Efficacy Data from Phase 1 KisMET-01 Study Supporting Best-in-Class Potential of Investigational cMET ADC, MYTX-011, in Non-Small Cell Lung Cancer - Business Wire

Mythic Therapeutics to Present Compelling Efficacy Data from Phase 1 KisMET-01 Study Supporting Best-in-Class Potential of Investigational cMET ADC, MYTX-011, in Non-Small Cell Lung Cancer Business Wire

Mythic Therapeutics Presents Initial Dose Escalation Data from Ongoing Phase 1 KisMET-01 Study on MYTX-011 at the American Society of Clinical Oncology (ASCO) Annual Meeting - Business Wire

Mythic Therapeutics Presents Initial Dose Escalation Data from Ongoing Phase 1 KisMET-01 Study on MYTX-011 at the American Society of Clinical Oncology (ASCO) Annual Meeting Business Wire

Mythic Therapeutics Presents Preclinical Data on Investigational cMET-Targeting Antibody-Drug Conjugate (ADC) MYTX-011 at American Association for Cancer Research (AACR) Annual Meeting - Business Wire

Mythic Therapeutics Presents Preclinical Data on Investigational cMET-Targeting Antibody-Drug Conjugate (ADC) MYTX-011 at American Association for Cancer Research (AACR) Annual Meeting Business Wire

Mythic Therapeutics Launches with New Approach to Improving Antibody Drug Conjugate Performance, Backed by $103 Million in Series B Financing - Business Wire

Mythic Therapeutics Launches with New Approach to Improving Antibody Drug Conjugate Performance, Backed by $103 Million in Series B Financing Business Wire

Companies like Mythic Therapeutics, Inc.

Ventus Therapeutics logo - Similar company to Mythic Therapeutics, Inc.

Ventus Therapeutics

88
Vertex Pharmaceuticals logo - Similar company to Mythic Therapeutics, Inc.

Vertex Pharmaceuticals

6.09K
enGene logo - Similar company to Mythic Therapeutics, Inc.

Engene

131
Mersana Therapeutics logo - Similar company to Mythic Therapeutics, Inc.

Mersana Therapeutics

128
Viridian Therapeutics, Inc. logo - Similar company to Mythic Therapeutics, Inc.

Viridian Therapeutic...

224
Beam Therapeutics logo - Similar company to Mythic Therapeutics, Inc.

Beam Therapeutics

557
Tessera Therapeutics logo - Similar company to Mythic Therapeutics, Inc.

Tessera Therapeutics

326
Kymera Therapeutics logo - Similar company to Mythic Therapeutics, Inc.

Kymera Therapeutics

250
Dragonfly Therapeutics, Inc. logo - Similar company to Mythic Therapeutics, Inc.

Dragonfly Therapeuti...

91
Tango Therapeutics logo - Similar company to Mythic Therapeutics, Inc.

Tango Therapeutics

168

Top Mythic Therapeutics, Inc. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant